News

In this webinar, NHF President and CEO Leonard A. Valentino, MD, discusses common questions about COVID-19 vaccines. Watch video. Source: National Hemophilia…

The federally funded hemophilia treatment center (HTC) network, with its model of a multidisciplinary care team (MDT) and regional infrastructure, has proven…

Enrollment for the Affordable Care Act 2021 health insurance is now open. Open enrollment runs through Tuesday, Dec. 15, 2020. Coverage begins…

The coronavirus case numbers in the US are not looking good. The COVID-19 Tracking Project is an excellent reason for both viewing…

A paused clinical trial of an Eli Lilly & Co. experimental antibody therapy won’t resume after federal researchers concluded the drug likely…

by Paul Clement Pain and hemophilia go hand-in-hand. During a joint or muscle bleed, blood fills the joint cavity or makes muscles…

The death of eminent Supreme Court justice Ruth Bader Ginsburg on September 18th brought renewed attention to the fate of the Affordable Care…

Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing Information (PI) for NUWIQ®,…

AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in…

There’s still time to PLAN YOUR VOTE!. If you’re a new voter, or not registered yet, use your voice and prepare yourself…

The election is right around the corner and there’s a lot of information to absorb. That is why the National Hemophilia Foundation…

A coalition of 33 organizations, including the National Hemophilia Foundation, representing millions of people with pre-existing conditions launched an unprecedented effort today…

Feeling disconnected from knowledge about women’s health and research? Get WIRED with the Hemophilia Federation of America (HFA) is seeking women with bleeding…

This summer’s Virtual Bleeding Disorders Conference (BDC) featured a pair of excellent public health symposiums, which were developed through an inspired collaboration…

The purpose of the study is to evaluate the efficacy and safety of this investigational gene therapy in patients with moderately severe…

This commentary was authored by six individuals with severe hemophilia, all of whom have worked to achieve better health outcomes for patients…

The recent news about the passing of United State Supreme Court Justice Ruth Bader Ginsburg and nomination of Judge Amy Coney Barrett…

NHF and HFA have been provided the following statement from CSL Behring. The statement says, in part: “Ferring Pharmaceuticals Inc. initiated a voluntary,…

The Milwaukee Unified Emergency Operations Center continues to put out up-to-date information for the citizens of Milwaukee County. This information is also…

The National Hemophilia Foundation (NHF) is working with the bleeding disorders community to envision our future for the next decade, and they…

Gene therapy for hemophilia remains a very active area of research, although it may take longer than expected. To discuss this, join…

The NHF is saddened by the loss of life and destruction of communities due to catastrophic fires in the west and a…

A recent commentary published in the journal Haemophilia, posits that while clinical trials for hemophilia gene therapy approach conclusion, there remain significant unanswered…

Sanofi recently announced results from their phase 1/2a EXTEN-A trial for their investigational therapy BIVV001, which were published in the New England Journal…